Mechanism for anti-interferon functions of influenza virus
流感病毒抗干扰素功能机制
基本信息
- 批准号:10216938
- 负责人:
- 金额:$ 36.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-20 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:Amino AcidsAntigensAntiviral AgentsAntiviral TherapyAreaAttenuatedBindingBiologicalCRISPR/Cas technologyCellsCo-ImmunoprecipitationsDataDevelopmentDiseaseDisease OutbreaksDoseEpithelial CellsEvolutionExonsFerretsGenesGenomeGenomicsGoalsHospitalizationHost DefenseHumanImmune EvasionImmunization ProgramsIn VitroInfluenzaInfluenza A virusInfluenza vaccinationInterferon Type IInterferonsInvadedKnockout MiceLungMass Spectrum AnalysisMembrane ProteinsMessenger RNAMolecularMusMutagenesisMutateMutationNational Institute of Allergy and Infectious DiseaseNatureNonstructural ProteinPathogenesisPathway interactionsPatternPhenotypePlayPolymerasePopulationPositioning AttributeProductionProteinsProteomicsResearchRoleSCID MiceSafetySeriesSignal PathwaySiteStrategic PlanningSurfaceSystemTestingVaccinationVaccinesViralViral GenomeViral Nonstructural ProteinsViral PhysiologyViral ProteinsVirusVirus ReplicationWild Type Mouseadaptive immune responsebasecDNA Librarydeep sequencingdensityimprovedin vivoinfluenza infectioninfluenza virus vaccineinfluenzavirusknockout genemouse modelmutantnovelpandemic diseasepathogenpathogenic virusprotein functionprotein protein interactionresponsescreeninguniversal influenza vaccineuniversal vaccinevirus host interaction
项目摘要
Project Summary
Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US.
The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN
response is known as the first important host defending mechanism to control influenza virus replication at
different steps, influenza virus has acquired many strategies to suppress/antagonize IFN function effectively
allowing its replication in the hosts. It is well known that influenza viral nonstructural protein 1 antagonizes IFN
function through suppressing IFN production. However, less is known on how influenza virus counteracts
function of IFN-stimulated genes (ISGs), many of which have antiviral functions. Our recently developed a
quantitative and high-throughput genomics system has enabled the identification of novel IFN-sensitive
mutations on multiple viral segments across influenza genome. The goal of this project is to determine how
influenza virus antagonizes host anti-viral mechanism by studying recently identified novel IFN-sensitive
mutations using a comprehensive genomic and proteomic platform in vitro and in vivo. The research plan
focuses on three motifs on influenza viral proteins PA, PB1, and M1. Each motif, represented by multiple
mutations located together in a small surface area, might target a cellular protein or step of IFNR signaling
pathway. In addition, our preliminary data suggest mutations on the M1 motif interact with IFN production
pathway, while motifs on PA and PB1 may counteract ISGs downstream of IFN production. The hypothesis is
that these three anti-IFN motifs of influenza PA, PB1, and M1 interact with cellular proteins to antagonize IFN
functions. A series of complementary approaches including high-density mutagenesis, mRNA display-deep
sequencing, ISG cDNA library screening, CRISPR/Cas9 gene editing, human lung primary culture system, and
gene knockout mice are proposed in three independent while logically connected Specific Aims (SAs) to test
our scientific hypothesis. SA#1 is to define the motifs on viral proteins PA, PB1, and M1 that are critical for the
anti-IFN functions. SA#2 is to utilize WT and mutant viral proteins containing IFN-sensitive mutations to
determine the cellular proteins interacting with the anti-IFN motifs. In SA#3 is to determine the functional
interaction and its biological impact in vitro and in vivo. The completion of proposed project will reveal
mechanism for the anti-IFN strategy used by influenza virus, advance our understanding of influenza
pathogenesis, and provide valuable targets for more effective influenza vaccine and anti-viral therapy.
项目摘要
在美国,甲型流感病毒在5-20%的人口中引起疾病,每年有超过200,000人住院。
流感病毒的抗原漂移和转移对流感疫苗接种计划提出了严峻的挑战。虽然IFN
应答被认为是控制流感病毒复制的第一个重要的宿主防御机制,
不同的步骤,流感病毒已经获得了许多策略来有效地抑制/拮抗IFN功能
允许其在主机中复制。众所周知,流感病毒非结构蛋白1拮抗IFN
通过抑制IFN的产生发挥作用。然而,对流感病毒如何抵消
干扰素刺激基因(ISG)的功能,其中许多具有抗病毒功能。我们最近开发的一种
定量和高通量的基因组学系统已经能够鉴定新的IFN-敏感的
流感病毒基因组中多个病毒片段的突变。这个项目的目标是确定如何
流感病毒拮抗宿主抗病毒机制研究新发现的干扰素敏感
使用全面的基因组和蛋白质组学平台在体外和体内研究突变。研究计划
重点关注流感病毒蛋白PA、PB 1和M1上的三个基序。每个主题,由多个
突变位于一起在一个小的表面积,可能针对细胞蛋白质或步骤的IFNR信号
通路此外,我们的初步数据表明M1基序上的突变与IFN的产生相互作用
PA和PB 1上的基序可能抵消IFN产生下游的ISG。这个假设是
流感病毒PA、PB 1和M1的这三种抗IFN基序与细胞蛋白相互作用以拮抗IFN
功能协调发展的一系列互补的方法,包括高密度诱变、mRNA深度展示
测序、ISG cDNA文库筛选、CRISPR/Cas9基因编辑、人肺原代培养系统,以及
基因敲除小鼠提出了三个独立的,而逻辑连接的特定目的(SA)进行测试
我们的科学假设SA#1是定义病毒蛋白PA、PB 1和M1上的基序,这些基序对病毒的免疫至关重要。
抗干扰素功能。SA#2是利用含有IFN敏感性突变的WT和突变病毒蛋白,
确定与抗IFN基序相互作用的细胞蛋白。在SA#3中,确定函数
相互作用及其在体外和体内的生物学影响。该项目的完成将揭示
针对流感病毒所采用的抗IFN策略的机制,推进我们对流感的认识
致病机理的研究,为更有效的流感疫苗和抗病毒治疗提供了有价值的靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yuan Shi其他文献
Yuan Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yuan Shi', 18)}}的其他基金
Determine the minimal level of replication required for broad protective immunity of influenza vaccine
确定流感疫苗广泛保护性免疫力所需的最低复制水平
- 批准号:
9886040 - 财政年份:2020
- 资助金额:
$ 36.02万 - 项目类别:
Determine the minimal level of replication required for broad protective immunity of influenza vaccine
确定流感疫苗广泛保护性免疫力所需的最低复制水平
- 批准号:
10084270 - 财政年份:2020
- 资助金额:
$ 36.02万 - 项目类别:
Mechanism for anti-interferon functions of influenza virus
流感病毒抗干扰素功能机制
- 批准号:
10634738 - 财政年份:2019
- 资助金额:
$ 36.02万 - 项目类别:
Mechanism for anti-interferon functions of influenza virus
流感病毒抗干扰素功能机制
- 批准号:
10408096 - 财政年份:2019
- 资助金额:
$ 36.02万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 36.02万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 36.02万 - 项目类别: